Insilico Medicine Company

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.


Connections from

Last Funding Type: Series D
Total Funding: 401300000
Last Funding Date: 2022-08-10
Funding Status: Late Stage Venture
Number Of Exists: 11-50
Employee Number: 101-250
Estimated Revenue: $1M to $10M
Investors Number: 32
Founded Date: 2014-01-01
Headquarters: Hong Kong, Hong Kong Island, Hong Kong
Industry: Anti-aging Therapies